Abstract
Immune checkpoint blockade represents a promising approach in oncology, showing anti-tumor activities in various cancers. However, although being generally far more well-tolerated than classical cytotoxic chemotherapy, this treatment, too, may be accompanied by considerable side effects and not all patients benefit equally. Therefore, careful patient selection and monitoring of the treatment response is mandatory. At present, checkpoint-specific molecular imaging is increasingly investigated as a tool for patient selection and response evaluation. Here, an overview of the current developments in immune checkpoint imaging is provided.
- Molecular Imaging
- Oncology: General
- Radioimmunoimaging
- Checkpoint blockade
- Molecular imaging
- Oncology
- PET/CT
- Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.